Altimmune: The High Cost Of Going Solo (Rating Downgrade)

Altimmune has received a rating downgrade due to concerns over its financial viability as it attempts to navigate the market independently. Analysts fear that the costs associated with developing its pipeline could outstrip available capital, placing pressure on the company's stock. This downgrade signals increased risk for investors, with potential downside ahead. The company's future prospects may hinge on its ability to secure funding or partnerships to mitigate expenses. Investors should watch for further updates regarding Altimmune's financial health and strategic direction.